Overview
The TIMC -
Reliable tracking of changes in lesion size or metabolism is essential for clinical trials that use radiological measurements as surrogate endpoints. The Tumor Metrics Core provides a service for managing these images, making measurements in a routine, reliable, and centralized way, and making results available to investigators efficiently.
Group Members
Core Co-Director: Gordon Harris, PhD (MGH)
Core Co-Director: Mathew Barish, MD (BWH)
Core Co-Director: Annick Van den Abbeele, MD (DFCI)
Core Manager
Bill Hanlon
Telephone: 617-632-6578
Email: whanlon@partners.org
Lead Image Analyst
Trinity Urban
Telephone: 617-643-0296
Email: turban@partners.org
Image Analysis Specialist
Rob Zondervan
Telephone: 617-462-0327
Email: rzondervan@partners.org
Research Fellows
Marta Braschi, MD
Telephone: 617-643-0106
Email: mbraschi@partners.org
Gisele Cruz, MD
Telephone: 617-643-0106
Email: gpcruz@partners.org
Xiaozhou MA, MD
Telephone: 617-643-0299
Email: xma@partners.org
Facilities & Equipment
Core Location
Massachusetts General Hospital, 3D Imaging Service
Services
The Tumor Metrics Core provides four primary services to DF/HCC investigators:
The Tumor Imaging Metrics Core will maintain a database of longitudinal radiological and clinical data that will link to the Quality Assurance for Clinical Trials (QACT) Core to provide an auditable record of quantitative measurements for clinical trials conducted through the DF/HCC.
Fee Schedule
Included in the TIMC user fees are the following services; consultation with Trial PIs prior to trial initiation, image study capture from DF/HCC centers, image study archival for the length of the trial, tumor measurements as specified in the protocol, database management of measurement results and image snapshots, web-based results reporting and assistance with trial audits with respect to the image analysis components of the trial.
The TIMC offers consultative services to clinical trials investigators at no additional cost to DF/HCC investigators. The goal of the consultative service is to optimize clinical trials’ protocol design for imaging acquisition and analysis methods so that trials are established with appropriate and optimal imaging methods.
TIMC service fees (per scan) -- New rates apply to 09-xxx trials, effective 13-June-2008
| Assessment Criteria | DF/HCC member | Non-DF/HCC member | Industry sponsored |
| RECIST ch/ab/pel (CT/MR) | $100 | $200 | $300 |
| WHO, IWRC, neuro, ch/ab/pel (CT/MR) | $200 | $300 | |
| Cheson (NHL) neck/ch/ab/pel (CT/MR) | $125 | $250 | $375 |
| SUV neuro, maximum of five lesions (PET) | $125 | $250 | $375 |
| SUV whole body, maximum of five lesions (PET) | $125 | $250 | $375 |
| Choi 6 (CT w/contrast) | $150 | $300 | $450 |
| NCI-96 (CT/MR) | $150 | $300 | $450 |
| 3D Volume – neuro, maximum of five lesions (MR) | $150 | $300 | $450 |
RECIST – Response Evaluation Criteria for Solid Tumors (linear).
WHO – World Health Organization criteria (bi-directional).
IWRC – International Workshop Response Criteria (bi-directional).
Cheson – (sum of products of perpendicular diameters). An additional charge of one scan time-point will be applied if measurements must be repeated from baseline; i.e. if new target lesions are identified for a subject in accordance with Cheson response criteria guidelines.
SUV – Standard Uptake Value, using body weight formula
Choi – RECIST plus density measurements on CT scans w/contrast
3D Volume - Includes modified RECIST measurements for brain.
Getting Started
Contact:
Core Manager
Bill Hanlon
Telephone: 617-632-6578
Email: whanlon@partners.org
Discover the largest hospital-based research program in the U.S. and how clinicians and scientists chart new terrain in biomedical research to treat and prevent human disease and bring the latest advances to patient care